Literature DB >> 16822289

The role of Janus kinases in haemopoiesis and haematological malignancy.

Asim Khwaja1.   

Abstract

The production of blood cells is regulated by a number of protein growth factors and cytokines that influence cell survival, proliferation and differentiation. Many of these molecules bind to cell surface receptors, which belong to a family of closely related cytokine receptors that lack intrinsic catalytic activity but are intimately associated with tyrosine kinases of the Janus kinase (JAK) family. Ligand binding induces the activation of JAKs, which sit at the apex of a signalling cascade in which a key role is played by members of the signal transducers and activators of transcription (STAT) group. Congenital deficiencies in JAK-STAT signalling are associated with immunodeficiency states and acquired activating mutations and translocations are involved in the pathophysiology of haematological malignancy. The latter findings have raised hopes that drugs that target aberrant JAK-STAT signalling may be useful for the treatment of human disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822289     DOI: 10.1111/j.1365-2141.2006.06206.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms.

Authors:  Michael H Guo; Satish K Nandakumar; Jacob C Ulirsch; Seyedeh M Zekavat; Jason D Buenrostro; Pradeep Natarajan; Rany M Salem; Roberto Chiarle; Mario Mitt; Mart Kals; Kalle Pärn; Krista Fischer; Lili Milani; Reedik Mägi; Priit Palta; Stacey B Gabriel; Andres Metspalu; Eric S Lander; Sekar Kathiresan; Joel N Hirschhorn; Tõnu Esko; Vijay G Sankaran
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-28       Impact factor: 11.205

2.  Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.

Authors:  Shashidhar S Jatiani; Stacey J Baker; Lewis R Silverman; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2010-10

Review 3.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Authors:  Emilee Senkevitch; Scott Durum
Journal:  Cytokine       Date:  2016-10-27       Impact factor: 3.861

4.  Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders.

Authors:  Emma Hammond; Kathryn Shaw; Benedict Carnley; Stephanie P'ng; Ian James; Richard Herrmann
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

Review 5.  Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia.

Authors:  Sampa Ghoshal Gupta; Heinz Baumann; Meir Wetzler
Journal:  Leuk Res       Date:  2008-01-14       Impact factor: 3.156

6.  Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Authors:  Vikas Gupta; Lynda Foltz; Shireen Sirhan; Lambert Busque; A Robert Turner
Journal:  Am J Blood Res       Date:  2012-09-23

7.  Intrinsic apoptotic pathways of gingival epithelial cells modulated by Porphyromonas gingivalis.

Authors:  Song Mao; Yoonsuk Park; Yoshiaki Hasegawa; Gena D Tribble; Chlöe E James; Martin Handfield; M Franci Stavropoulos; Ozlem Yilmaz; Richard J Lamont
Journal:  Cell Microbiol       Date:  2007-04-05       Impact factor: 3.715

Review 8.  Janus kinase deregulation in leukemia and lymphoma.

Authors:  Edwin Chen; Louis M Staudt; Anthony R Green
Journal:  Immunity       Date:  2012-04-20       Impact factor: 31.745

9.  Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans.

Authors:  Sung O Park; Heather L Wamsley; Kyungmi Bae; Zhongbo Hu; Xiaomiao Li; Se-woon Choe; William B Slayton; S Paul Oh; Kay-Uwe Wagner; Peter P Sayeski
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

Review 10.  The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics.

Authors:  Michalis V Karamouzis; Panagiotis A Konstantinopoulos; Athanasios G Papavassiliou
Journal:  J Mol Med (Berl)       Date:  2007-01-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.